Cincinnati-based contract research organization (CRO) Medpace acquired medical device CRO Symbios for an undisclosed amount. Symbios was advised by Fairmount Partners in this transaction.

Symbios supports medical device research with experience in pre-market, post-approval and post-market clinical trials. The company will continue to operate out of its Minneapolis, Minn., headquarters. Symbios’ founder and CEO Ryan Wilson and his management team will continue to lead Medpace’s medical device business, now named Symbios Clinical, as a member of the Medpace group of companies.

“The ability of Medpace to tap into this innovative company for benefit of our existing and new Sponsors will be valuable as yet another service area for Medpace, and allow Symbios to benefit from our established global infrastructure,” said Medpace president and CEO August Troendle in a statement.

Medpace offers services in phase I to IV clinical trial management, bio-imaging, central laboratory and clinical pharmacology. The CRO has European headquarters in The Netherlands, Asian headquarters in Singapore and regional offices throughout Europe, Asia, Australia, South Africa and the Americas.

Earlier this year, the company acquired Germany-based CRO Medical Consulting Dr. Schlichtiger. At the time, Medpace had 1,000 employees worldwide but announced plans to almost double its headcount by 2014.